+------------------------------------------------------------------------------+
Novo Nordisk Sees Sales More Than Doubling in 10 Yrs: Berlingske 2014-12-27 11:18:46.392 GMT
By Katarina Gustafsson (Bloomberg) -- If co. receives approval for Tresiba in the U.S. then can see avg. growth of 10% a year for the next five years, CEO Lars Rebien Sorensen tells Berlingske. * Says 80%-85% of growth will come from diabetes * Main section of growth set to be in U.S., but also from China and other growth markets outside Europe * NOTE Dec. 19: EMA Gives Positive Recommendation for Novo Nordisk’s Tresiba
For Related News and Information: First Word scrolling panel: FIRST<GO> First Word newswire: NH BFW<GO>
To contact the reporter on this story: Katarina Gustafsson in Stockholm at +46-8-610-0714 or kgustafsson@bloomberg.net To contact the editor responsible for this story: Celeste Perri at +31-20-589-8505 or cperri@bloomberg.net